India & Sun Pharma
8 shared events · Importance 4 · Last updated Apr 08, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
International
India: As an import-dependent economy, India faces dual pressure from rising Brent Crude prices, leading to increased inflation expectations and stress on corporate margins, causing its stock markets to decline.
Sun Pharma: Sun Pharma was among the major laggards in the S&P BSE Sensex firms.
Apr 23, 2026 · 14 articles
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Sun Pharma: Sun Pharma is among the Indian generic drugmakers expected to introduce lower-priced versions of semaglutide after Semaglutide's patent expires.
Nov 11, 2025 · 6 articles
Domestic
India: Indian equities staged a recovery despite the rupee hitting a record low and crude remaining elevated. Investor confidence was bolstered by anticipation of potential government measures to mitigate INR weakness.
Sun Pharma: Sun Pharma was among the gainers.
May 14, 2026 · 6 articles
International
Sun Pharma: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how India and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard